Answers are grounded in this paper and cite their sources.
In vitro analysis of “probably benign” MET TKD mutations in Ba/F3 cells. (A) Phosphorylation of MET was analyzed in Ba/F3 cells stably transduced with MET TKD mutants. MET H1094Y and F1200I were included as positive controls for oncogenic mutations (OncoKB, also detected in the two patient cases) and MET WT was included as negative control. (B) IL-3-independent cell proliferation of Ba/F3 cells expressing “probably benign” MET TKD mutants, shown by relative spheroid size measured daily from day 1 to day 7. (C) Spheroid images of Ba/F3 cells expressing MET TKD mutants taken on day 1 and day 7.
No takes yet. Share an insight, caveat, or question.
Pecci et al. (2024) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: